Subsequent Events	9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events On November 12, 2025, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC, as representative of the several underwriters named therein (the “Underwriters”), in connection with the underwritten public offering and sale by the Company (the “2025 Underwritten Offering”) of 15,152,485 shares of the Company’s common stock at a public offering price of $1.65 per share (the “Common Stock Purchase Price”), and pre-funded warrants (the “2025 Pre-Funded Warrants”) at a public offering price of $1.649 per 2025 Pre-Funded Warrant, which are exercisable to purchase up to 15,151,515 shares of common stock at an exercise price of $0.001 per share. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters an option (the “Option”), exercisable for 30 days, to purchase up to 4,545,600 additional shares of common stock at the Common Stock Purchase Price less the underwriting discounts and commissions, which Option has been exercised in full by the Underwriters. The 2025 Underwritten Offering closed on November 13, 2025. The estimated net proceeds to the Company from the 2025 Underwritten Offering, after deducting the Underwriters’ discounts and commissions and the Company’s estimated offering expenses, was approximately $53.6 million, including net proceeds from the Underwriters exercise of the Option.

Subsequent Events

9 Months Ended

Sep. 30, 2025

Note 12. Subsequent Events

On November 12, 2025, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC, as representative of the several underwriters named therein (the “Underwriters”), in connection with the underwritten public offering and sale by the Company (the “2025 Underwritten Offering”) of 15,152,485 shares of the Company’s common stock at a public offering price of $1.65 per share (the “Common Stock Purchase Price”), and pre-funded warrants (the “2025 Pre-Funded Warrants”) at a public offering price of $1.649 per 2025 Pre-Funded Warrant, which are exercisable to purchase up to 15,151,515 shares of common stock at an exercise price of $0.001 per share. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters an option (the “Option”), exercisable for 30 days, to purchase up to 4,545,600 additional shares of common stock at the Common Stock Purchase Price less the underwriting discounts and commissions, which Option has been exercised in full by the Underwriters. The 2025 Underwritten Offering closed on November 13, 2025. The estimated net proceeds to the Company from the 2025 Underwritten Offering, after deducting the Underwriters’ discounts and commissions and the Company’s estimated offering expenses, was approximately $53.6 million, including net proceeds from the Underwriters exercise of the Option.